Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)

This is an interventional treatment trial for Coronary Artery Disease Read More

Inclusion Criteria:

• Be at least 18 years old, male or female
• Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago)
• LDL > 100 mg/dl
• HDL < 50 mg/dl
• Triglycerides < 400 mg/dl
• No Nicotine abuse for at least 3 months
• Statin-therapy for more than 4 weeks
• Give a written informed consent
• Have the ability to understand the requirements of the study, and agree and be able to return for the required assessments.

Exclusion Criteria:

• Women of childbearing potential, pregnancy or being lactating
• Current participation in another clinical trial
• Have other severe concurrent illness (e.g., active infection, malignancy)
• Have a history of alcohol or drug abuse within 3 months of admission or factors making follow-up difficult or unlikely.
• Have significant or unexplained liver dysfunction or chronic increased levels of transaminases (ALT, AST)
• Suffer from myopathy, active peptic disease or arterial bleeding
• Have a known hypersensitivity against niacin or statins
• Are actually treated with any of itraconazole, ketoconazole, HIV-Protease-Inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone.
• Actual therapy with ezetimibe
• Diabetes mellitus Type I